Logo image of KYMR

KYMERA THERAPEUTICS INC (KYMR) Stock Fundamental Analysis

USA - NASDAQ:KYMR - US5015751044 - Common Stock

57.76 USD
+1.96 (+3.51%)
Last: 10/23/2025, 8:14:04 PM
57.76 USD
0 (0%)
After Hours: 10/23/2025, 8:14:04 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to KYMR. KYMR was compared to 534 industry peers in the Biotechnology industry. KYMR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. KYMR does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year KYMR has reported negative net income.
In the past year KYMR has reported a negative cash flow from operations.
KYMR had negative earnings in each of the past 5 years.
KYMR had negative operating cash flow in 4 of the past 5 years.
KYMR Yearly Net Income VS EBIT VS OCF VS FCFKYMR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M

1.2 Ratios

With a decent Return On Assets value of -24.35%, KYMR is doing good in the industry, outperforming 73.41% of the companies in the same industry.
KYMR has a Return On Equity of -28.35%. This is in the better half of the industry: KYMR outperforms 78.65% of its industry peers.
Industry RankSector Rank
ROA -24.35%
ROE -28.35%
ROIC N/A
ROA(3y)-24.69%
ROA(5y)-20.37%
ROE(3y)-31.86%
ROE(5y)-27.33%
ROIC(3y)N/A
ROIC(5y)N/A
KYMR Yearly ROA, ROE, ROICKYMR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for KYMR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KYMR Yearly Profit, Operating, Gross MarginsKYMR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -500 -1K

More info and screens

5

2. Health

2.1 Basic Checks

KYMR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for KYMR has been increased compared to 1 year ago.
KYMR has more shares outstanding than it did 5 years ago.
KYMR has a better debt/assets ratio than last year.
KYMR Yearly Shares OutstandingKYMR Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
KYMR Yearly Total Debt VS Total AssetsKYMR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

KYMR has an Altman-Z score of 13.70. This indicates that KYMR is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of KYMR (13.70) is better than 86.52% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that KYMR is not too dependend on debt financing.
The Debt to Equity ratio of KYMR (0.00) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 13.7
ROIC/WACCN/A
WACC9.31%
KYMR Yearly LT Debt VS Equity VS FCFKYMR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

KYMR has a Current Ratio of 8.32. This indicates that KYMR is financially healthy and has no problem in meeting its short term obligations.
KYMR's Current ratio of 8.32 is fine compared to the rest of the industry. KYMR outperforms 74.53% of its industry peers.
KYMR has a Quick Ratio of 8.32. This indicates that KYMR is financially healthy and has no problem in meeting its short term obligations.
KYMR has a better Quick ratio (8.32) than 74.91% of its industry peers.
Industry RankSector Rank
Current Ratio 8.32
Quick Ratio 8.32
KYMR Yearly Current Assets VS Current LiabilitesKYMR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for KYMR have decreased strongly by -47.66% in the last year.
Looking at the last year, KYMR shows a very negative growth in Revenue. The Revenue has decreased by -49.51% in the last year.
KYMR shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 74.25% yearly.
EPS 1Y (TTM)-47.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-63.79%
Revenue 1Y (TTM)-49.51%
Revenue growth 3Y-13.54%
Revenue growth 5Y74.25%
Sales Q2Q%-55.26%

3.2 Future

KYMR is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -8.55% yearly.
Based on estimates for the next years, KYMR will show a small growth in Revenue. The Revenue will grow by 5.79% on average per year.
EPS Next Y-20.39%
EPS Next 2Y-19.95%
EPS Next 3Y-15.23%
EPS Next 5Y-8.55%
Revenue Next Year46.34%
Revenue Next 2Y4.03%
Revenue Next 3Y4.08%
Revenue Next 5Y5.79%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
KYMR Yearly Revenue VS EstimatesKYMR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B 2.5B
KYMR Yearly EPS VS EstimatesKYMR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

KYMR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KYMR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KYMR Price Earnings VS Forward Price EarningsKYMR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KYMR Per share dataKYMR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

A cheap valuation may be justified as KYMR's earnings are expected to decrease with -15.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-19.95%
EPS Next 3Y-15.23%

More info and screens

0

5. Dividend

5.1 Amount

KYMR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KYMERA THERAPEUTICS INC

NASDAQ:KYMR (10/23/2025, 8:14:04 PM)

After market: 57.76 0 (0%)

57.76

+1.96 (+3.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/bmo
Earnings (Next)10-30 2025-10-30/bmo
Inst Owners109.33%
Inst Owner Change0%
Ins Owners1.45%
Ins Owner Change4.61%
Market Cap4.13B
Revenue(TTM)44.71M
Net Income(TTM)-275434000
Analysts88.15
Price Target64.31 (11.34%)
Short Float %10.78%
Short Ratio10.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.36%
Min EPS beat(2)-14.98%
Max EPS beat(2)12.26%
EPS beat(4)2
Avg EPS beat(4)-2.49%
Min EPS beat(4)-14.98%
Max EPS beat(4)12.26%
EPS beat(8)5
Avg EPS beat(8)3.14%
EPS beat(12)6
Avg EPS beat(12)1.66%
EPS beat(16)6
Avg EPS beat(16)-2.46%
Revenue beat(2)1
Avg Revenue beat(2)30.73%
Min Revenue beat(2)-51.89%
Max Revenue beat(2)113.36%
Revenue beat(4)1
Avg Revenue beat(4)-10.45%
Min Revenue beat(4)-64.6%
Max Revenue beat(4)113.36%
Revenue beat(8)3
Avg Revenue beat(8)-3.36%
Revenue beat(12)4
Avg Revenue beat(12)-9.37%
Revenue beat(16)5
Avg Revenue beat(16)-12.7%
PT rev (1m)1.52%
PT rev (3m)4.99%
EPS NQ rev (1m)-0.43%
EPS NQ rev (3m)9.49%
EPS NY rev (1m)-0.23%
EPS NY rev (3m)2.07%
Revenue NQ rev (1m)-1.68%
Revenue NQ rev (3m)14.8%
Revenue NY rev (1m)-1%
Revenue NY rev (3m)2.43%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 92.37
P/FCF N/A
P/OCF N/A
P/B 4.25
P/tB 4.25
EV/EBITDA N/A
EPS(TTM)-3.47
EYN/A
EPS(NY)-4.17
Fwd EYN/A
FCF(TTM)-3.54
FCFYN/A
OCF(TTM)-3.51
OCFYN/A
SpS0.63
BVpS13.59
TBVpS13.59
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -24.35%
ROE -28.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-24.69%
ROA(5y)-20.37%
ROE(3y)-31.86%
ROE(5y)-27.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 23.55%
Cap/Sales 4.27%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.32
Quick Ratio 8.32
Altman-Z 13.7
F-Score1
WACC9.31%
ROIC/WACCN/A
Cap/Depr(3y)412.2%
Cap/Depr(5y)364.06%
Cap/Sales(3y)25.74%
Cap/Sales(5y)21.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-47.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-63.79%
EPS Next Y-20.39%
EPS Next 2Y-19.95%
EPS Next 3Y-15.23%
EPS Next 5Y-8.55%
Revenue 1Y (TTM)-49.51%
Revenue growth 3Y-13.54%
Revenue growth 5Y74.25%
Sales Q2Q%-55.26%
Revenue Next Year46.34%
Revenue Next 2Y4.03%
Revenue Next 3Y4.08%
Revenue Next 5Y5.79%
EBIT growth 1Y-72.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.66%
EBIT Next 3Y-20.51%
EBIT Next 5YN/A
FCF growth 1Y-49.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-64.06%
OCF growth 3YN/A
OCF growth 5YN/A